Oregon Health & Science University researchers identified a drug combination—venetoclax (BCL2 inhibitor) plus palbociclib (CDK4/6 inhibitor)—that produced stronger, more durable anti‑leukemia activity than venetoclax alone in preclinical AML models and human tissue samples. Published in Cell Reports Medicine, the work screened 25 combinations and found venetoclax plus palbociclib co‑targets cell‑cycle and protein synthesis pathways, mitigating known resistance mechanisms to current frontline regimens. The team validated efficacy in mouse xenografts and human samples and suggested the combination could inform clinical strategies to delay or overcome treatment resistance in AML.